Quality of Life and Symptomatic Response in Myelofibrosis Patients Receiving an Allogeneic Stem Cell Transplant


About this study

The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients must have myelofibrosis (MF) including primary MF, Post-ET, or Post–PV MF.
  • Patients must be planning to undergo allogeneic HSCT (matched or mismatched  related/matched or mismatched unrelated with HLA typing completed during initial stem cell transplant evaluation).
  • Participants must be willing to complete a packet of metrics (MPN-SAF and FACT-BMT) at the pre-transplant evaluation (within one month of start of conditioning), day 30, day 100 and 1 year post-transplant and sign informed consent (see attached)  prior to enrollment.  Metric packages will be available in English, Italian, Swedish, French, German, Dutch, and Spanish.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jeanne Palmer, M.D.

Closed for enrollment

Contact information:

Regina Becker

(480) 342-6079


More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer